Vanguard Group
ANAC

Vanguard Group’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Vanguard Group’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,889,546
Closed -$154M – 4227
2016
Q1 		$154M Buy
2,889,546
+192,062
+7% +$14.2M 0.01% 1177
2015
Q4 		$305M Buy
2,697,484
+78,122
+3% +$8.61M 0.02% 785
2015
Q3 		$308M Buy
2,619,362
+179,701
+7% +$23.5M 0.02% 755
2015
Q2 		$189M Buy
2,439,661
+140,111
+6% +$9.19M 0.01% 1086
2015
Q1 		$133M Buy
2,299,550
+571,910
+33% +$24.3M 0.01% 1298
2014
Q4 		$55.7M Buy
1,727,640
+605,986
+54% +$18.2M ﹤0.01% 1781
2014
Q3 		$27.4M Buy
1,121,654
+180,651
+19% +$3.67M ﹤0.01% 2088
2014
Q2 		$16.7M Buy
941,003
+43,287
+5% +$697K ﹤0.01% 2283
2014
Q1 		$18M Buy
897,716
+152,476
+20% +$2.96M ﹤0.01% 2232
2013
Q4 		$12.5M Buy
745,240
+44,689
+6% +$618K ﹤0.01% 2358
2013
Q3 		$7.44M Buy
700,551
+2,057
+0.3% +$18K ﹤0.01% 2541
2013
Q2 		$3.9M Buy
+698,494
New +$4.23M ﹤0.01% 2793

Other funds holding ANAC

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Vanguard Group's ANAC Position: Q2 2016 in Review

Vanguard Group sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 2,889,546 shares — an estimated $154M sold.

Vanguard Group first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $308M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Vanguard Group reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Vanguard Group sold 2,889,546 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $154M.
  • Vanguard Group first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Vanguard Group's ANACOR PHARMACEUTICALS INC COM position peaked at $308M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Vanguard Group's 13F filing for Q2 2016, filed 10 Aug 2016.